{"id":40719,"date":"2025-09-04T16:20:44","date_gmt":"2025-09-04T08:20:44","guid":{"rendered":"https:\/\/flcube.com\/?p=40719"},"modified":"2025-09-04T16:20:45","modified_gmt":"2025-09-04T08:20:45","slug":"hengruis-shr%e2%80%91a2009-adc-gains-nmpa-approval-for-her3%e2%80%91targeted-tumor-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40719","title":{"rendered":"Hengrui\u2019s SHR\u2011A2009 ADC Gains NMPA Approval for HER3\u2011Targeted Tumor Therapy"},"content":{"rendered":"\n<p>China\u2011based\u00a0<strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>) announced that the <strong>China National Medical Products Administration (NMPA)<\/strong> has approved an open\u2011label, multicenter Phase\u202f1b\/2 clinical trial of its novel antibody\u2011drug conjugate (ADC) <strong>SHR\u2011A2009<\/strong> in combination with existing anti\u2011tumor therapies for patients with advanced solid tumors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-is-shr-a2009\">What Is SHR\u2011A2009?<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target<\/strong> \u2013 Human epidermal growth factor receptor\u20113 (HER3) expressed on the surface of many solid\u2011tumor cells.<\/li>\n\n\n\n<li><strong>Mechanism<\/strong> \u2013 The ADC binds HER3, is internalized, and delivers a cytotoxic payload via lysosomal hydrolysis, selectively killing HER3\u2011positive tumor cells.<\/li>\n\n\n\n<li><strong>Innovation<\/strong> \u2013 No other HER3\u2011targeted ADC has received global marketing approval, positioning SHR\u2011A2009 as a first\u2011in\u2011class candidate.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NMPA Clearance<\/strong> \u2013 The agency approved the initiation of a Phase\u202f1b\/2 study, allowing Hengrui to evaluate safety, tolerability, and preliminary efficacy in a real\u2011world, combination\u2011therapy setting.<\/li>\n\n\n\n<li><strong>Trial Design<\/strong> \u2013 Open\u2011label, multicenter, enrolling patients with advanced solid tumors who are receiving standard anti\u2011tumor regimens.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investment-amp-development\">Investment &amp; Development<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>R&amp;D Spend<\/strong> \u2013 The cumulative research and development investment for SHR\u2011A2009 has reached <strong>\u2248 RMB\u202f197.74\u202fmillion<\/strong> (\u2248\u202fUS$\u202f28\u202fmillion).<\/li>\n\n\n\n<li><strong>Pipeline Positioning<\/strong> \u2013 This investment underscores Hengrui\u2019s commitment to expanding its ADC portfolio and to addressing unmet needs in oncology.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-implications\">Market Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Landscape<\/strong> \u2013 By targeting HER3, SHR\u2011A2009 fills a therapeutic niche where most ADCs focus on HER2, EGFR, or CD33.<\/li>\n\n\n\n<li><strong>Strategic Advantage<\/strong> \u2013 Early\u2011phase data will guide dose\u2011optimization and potential combination partners, enhancing Hengrui\u2019s positioning in the global ADC market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/600276_20250903_SJK7.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600276_20250903_SJK7.\"><\/object><a id=\"wp-block-file--media-0a0e776d-3791-42f4-9078-9e80e59da64f\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/600276_20250903_SJK7.pdf\">600276_20250903_SJK7<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/600276_20250903_SJK7.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-0a0e776d-3791-42f4-9078-9e80e59da64f\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based\u00a0Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that the China National Medical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40723,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,16,62,4228,852],"class_list":["post-40719","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-cancer","tag-clinical-trial-approval-initiation","tag-hkg-1276","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui\u2019s SHR\u2011A2009 ADC Gains NMPA Approval for HER3\u2011Targeted Tumor Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2019s Jiangsu\u202fHengrui Pharmaceuticals (SHA: 600276, HKG: 1276) has won NMPA clearance to launch an open\u2011label Phase\u202f1b\/2 trial of its HER3\u2011targeted antibody\u2011drug conjugate **SHR\u2011A2009** in combination with standard anti\u2011tumor regimens for advanced solid\u2011tumor patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40719\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui\u2019s SHR\u2011A2009 ADC Gains NMPA Approval for HER3\u2011Targeted Tumor Therapy\" \/>\n<meta property=\"og:description\" content=\"China\u2019s Jiangsu\u202fHengrui Pharmaceuticals (SHA: 600276, HKG: 1276) has won NMPA clearance to launch an open\u2011label Phase\u202f1b\/2 trial of its HER3\u2011targeted antibody\u2011drug conjugate **SHR\u2011A2009** in combination with standard anti\u2011tumor regimens for advanced solid\u2011tumor patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40719\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-04T08:20:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-04T08:20:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0415.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40719#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40719\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui\u2019s SHR\u2011A2009 ADC Gains NMPA Approval for HER3\u2011Targeted Tumor Therapy\",\"datePublished\":\"2025-09-04T08:20:44+00:00\",\"dateModified\":\"2025-09-04T08:20:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40719\"},\"wordCount\":264,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40719#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0415.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"HKG: 1276\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40719#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40719\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40719\",\"name\":\"Hengrui\u2019s SHR\u2011A2009 ADC Gains NMPA Approval for HER3\u2011Targeted Tumor Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40719#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40719#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0415.webp\",\"datePublished\":\"2025-09-04T08:20:44+00:00\",\"dateModified\":\"2025-09-04T08:20:45+00:00\",\"description\":\"China\u2019s Jiangsu\u202fHengrui Pharmaceuticals (SHA: 600276, HKG: 1276) has won NMPA clearance to launch an open\u2011label Phase\u202f1b\\\/2 trial of its HER3\u2011targeted antibody\u2011drug conjugate **SHR\u2011A2009** in combination with standard anti\u2011tumor regimens for advanced solid\u2011tumor patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40719#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40719\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40719#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0415.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0415.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hengrui\u2019s SHR\u2011A2009 ADC Gains NMPA Approval for HER3\u2011Targeted Tumor Therapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40719#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui\u2019s SHR\u2011A2009 ADC Gains NMPA Approval for HER3\u2011Targeted Tumor Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui\u2019s SHR\u2011A2009 ADC Gains NMPA Approval for HER3\u2011Targeted Tumor Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2019s Jiangsu\u202fHengrui Pharmaceuticals (SHA: 600276, HKG: 1276) has won NMPA clearance to launch an open\u2011label Phase\u202f1b\/2 trial of its HER3\u2011targeted antibody\u2011drug conjugate **SHR\u2011A2009** in combination with standard anti\u2011tumor regimens for advanced solid\u2011tumor patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40719","og_locale":"en_US","og_type":"article","og_title":"Hengrui\u2019s SHR\u2011A2009 ADC Gains NMPA Approval for HER3\u2011Targeted Tumor Therapy","og_description":"China\u2019s Jiangsu\u202fHengrui Pharmaceuticals (SHA: 600276, HKG: 1276) has won NMPA clearance to launch an open\u2011label Phase\u202f1b\/2 trial of its HER3\u2011targeted antibody\u2011drug conjugate **SHR\u2011A2009** in combination with standard anti\u2011tumor regimens for advanced solid\u2011tumor patients.","og_url":"https:\/\/flcube.com\/?p=40719","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-04T08:20:44+00:00","article_modified_time":"2025-09-04T08:20:45+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0415.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40719#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40719"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui\u2019s SHR\u2011A2009 ADC Gains NMPA Approval for HER3\u2011Targeted Tumor Therapy","datePublished":"2025-09-04T08:20:44+00:00","dateModified":"2025-09-04T08:20:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40719"},"wordCount":264,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40719#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0415.webp","keywords":["ADC \/ XDC","Cancer","Clinical trial approval \/ initiation","HKG: 1276","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40719#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40719","url":"https:\/\/flcube.com\/?p=40719","name":"Hengrui\u2019s SHR\u2011A2009 ADC Gains NMPA Approval for HER3\u2011Targeted Tumor Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40719#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40719#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0415.webp","datePublished":"2025-09-04T08:20:44+00:00","dateModified":"2025-09-04T08:20:45+00:00","description":"China\u2019s Jiangsu\u202fHengrui Pharmaceuticals (SHA: 600276, HKG: 1276) has won NMPA clearance to launch an open\u2011label Phase\u202f1b\/2 trial of its HER3\u2011targeted antibody\u2011drug conjugate **SHR\u2011A2009** in combination with standard anti\u2011tumor regimens for advanced solid\u2011tumor patients.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40719#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40719"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40719#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0415.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0415.webp","width":1080,"height":608,"caption":"Hengrui\u2019s SHR\u2011A2009 ADC Gains NMPA Approval for HER3\u2011Targeted Tumor Therapy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40719#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui\u2019s SHR\u2011A2009 ADC Gains NMPA Approval for HER3\u2011Targeted Tumor Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0415.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40719","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40719"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40719\/revisions"}],"predecessor-version":[{"id":40724,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40719\/revisions\/40724"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40723"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40719"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40719"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40719"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}